Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium Tuberculosis

References

• World Health Organization. Global tuberculosis report 2021. World Health Organization; 2021.
   Google Scholar
• Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010;375(9728):1830–1843. doi:10.1016/S0140-6736(10)60410-2
   PubMed Web of Science ®Google Scholar
• Sun F, Li Y, Chen Y, et al. Introducing molecular testing pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study. Eur Respir J. 2019;53(3):1801770. doi:10.1183/13993003.01770-2018
   Web of Science ®Google Scholar
• Zhang Y, Mitchison D, Shi W, Zhang W. Mechanisms of pyrazinamide action and resistance. Microbiol Spectr. 2014;2:1–12. doi:10.1128/microbiolspec.MGM2-0023-2013
   Google Scholar
• Nahid P, Dorman SE, Alipanah N, et al. Executive Summary: official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63:e147. doi:10.1093/cid/ciw376
   PubMed Web of Science ®Google Scholar
• Kempker RR, Heinrichs MT, Nikolaishvili K, et al. Lung tissue concentrations of pyrazinamide among patients with drug-resistant pulmonary tuberculosis. Antimicrob Agents Chemother. 2017;61. doi:10.1128/AAC.00226-17
   Web of Science ®Google Scholar
• Somner AR. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First report: results during chemotherapy. Br J Dis Chest. 1981;75:141–153. doi:10.1016/0007-0971(81)90046-2
   Google Scholar
• World Health Organization. Rapid communication: key changes to treatment of multidrug-and rifampicin- resistant tuberculosis (MDR/RR-TB). World Health Organization; 2018.
   Google Scholar
• Van Deun A, Maug AKJ, Salim MAH, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684–692. doi:10.1164/rccm.201001-0077OC
   PubMed Web of Science ®Google Scholar
• Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49:1602308. doi:10.1183/13993003.02308-2016
   PubMed Web of Science ®Google Scholar
• Moodley R, Godec TR. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev. 2016;25:29–35. doi:10.1183/16000617.0080-2015
   PubMed Web of Science ®Google Scholar
• Lan N, Master I, Phillips PP, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. NEJM. 2019;380:1201–1213.
   Web of Science ®Google Scholar
• Bouton TC, Phillips PPJ, Mitnick CD, et al. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Trials. 2017;18:563. doi:10.1186/s13063-017-2292-x
   PubMed Web of Science ®Google Scholar
• Cellamare M, Ventz S, Baudin E, Mitnick CD, Trippa L. A Bayesian response-adaptive trial in tuberculosis: the end-TB trial. Clin Trials. 2016;14:17–28.
   Web of Science ®Google Scholar
• Weng T, Sun F, Li Y, et al. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial. BMC Infect Dis. 2021;21(1). doi:10.1186/s12879-021-05870-w
   Web of Science ®Google Scholar
• Hussain Z, Zhu J, Ma X. Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug. Drug Metab Dispos. 2021;49(8):679–682. doi:10.1124/dmd.121.000389
   PubMed Web of Science ®Google Scholar
• Scorpio A, Lindholm-Levy P, Heifets L, et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1997;41(3):540–543. doi:10.1128/AAC.41.3.540
   PubMed Web of Science ®Google Scholar
• Mestdagh M, Fonteyne PA, Realini L, et al. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1999;43(9):2317–2319. doi:10.1128/AAC.43.9.2317
   Web of Science ®Google Scholar
• Stoffels K, Mathys V, Fauville-Dufaux M, Wintjens R, Bifani P. Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012;56(10):5186–5193.
   Web of Science ®Google Scholar
• Whitfield MG, Soeters HM, Warren RM, et al. A global perspective on pyrazinamide resistance: systematic review and meta-analysis. PLoS One. 2015;10(7):e0133869. doi:10.1371/journal.pone.0133869
   PubMed Web of Science ®Google Scholar
• Shi D, Li L, Zhao Y, et al. Characteristics of embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates in Henan, China. J Antimicrob Chemother. 2011;66:2240–2247. doi:10.1093/jac/dkr284
   Web of Science ®Google Scholar
• Sheen P, Ferrer P, Gilman RH, et al. Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis. 2009;89:109–113. doi:10.1016/j.tube.2009.01.004
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen J, Shen X, et al. Highly polymorphic variable-number tandem repeats loci for differentiating Beijing genotype strains of Mycobacterium tuberculosis in Shanghai, China. FEMS Microbiol Lett. 2008;282:22–31. doi:10.1111/j.1574-6968.2008.01081.x
   Web of Science ®Google Scholar
• Chen J, Tsolaki AG, Shen X, Jiang X, Mei J, Gao Q. Deletion-targeted multiplex PCR (DTM-PCR) for identification of Beijing/W genotypes of Mycobacterium tuberculosis. Tuberculosis. 2007;87:446–449. doi:10.1016/j.tube.2007.05.014
   PubMed Web of Science ®Google Scholar
• O’Mahony J, Hill C. Rapid real-time PCR assay for detection and quantitation of Mycobacterium avium subsp. paratuberculosis DNA in artificially contaminated milk. Appl Environ Microbiol. 2004;70(8):4561–4568. doi:10.1128/AEM.70.8.4561-4568.2004
   Web of Science ®Google Scholar
• Sheen P. Molecular Diagnosis of Pyrazinamide Resistance and Molecular Understanding of the Pyrazinamidase Functionality in Mycobacterium Tuberculosis. Baltimore, MD: Johns Hopkins University; 2008.
   Google Scholar
• Gopal P, Grüber G, Dartois V, Dick T. Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide. Trends Pharmacol Sci. 2019;40(12):930–940. doi:10.1016/j.tips.2019.10.005
   PubMed Web of Science ®Google Scholar
• Aono A, Chikamatsu K, Yamada H, Kato T, Mitarai S. Association between pncA gene mutations, pyrazinamidase activity, and pyrazinamide susceptibility testing in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58:4928–4930. doi:10.1128/AAC.02394-14
   PubMed Web of Science ®Google Scholar
• Singh P, Mishra AK, Malonia SK, et al. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria. J Commun Dis. 2006;38:288–298.
   PubMedGoogle Scholar
• Chinese Ministry of Health. National Baseline Survey of Drug-Resistant Tuberculosis (2007–2008). People’s Medical Publishing House; 2010.
   Google Scholar
• World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: World Health Organization; 2010.
   Google Scholar
• World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis −2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: World Health Organization; 2011.
   Google Scholar
• Li S-Y, Tasneen R, Tyagi S, et al. Bactericidal and sterilizing activity of a novel regimen with Bedaquiline, Pretomanid, Moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother. 2017;61(9):e00913–7 e00913–17. doi:10.1128/AAC.00913-17
   Web of Science ®Google Scholar
• Njire M, Tan Y, Mugweru J, et al. Pyrazinamide resistance in mycobacterium tuberculosis: review and update. Adv Med Sci. 2016;61(1):63–71. doi:10.1016/j.advms.2015.09.007
   PubMed Web of Science ®Google Scholar
• Salfinger M, Heifets LB. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother. 1988;32:1002–1004. doi:10.1128/AAC.32.7.1002
   PubMed Web of Science ®Google Scholar
• Heifets L. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol. 2002;51:11–12.
   Web of Science ®Google Scholar
• Pfyffer GE, Palicova F, Rusch-Gerdes S. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system. J Clin Microbiol. 2002;40:1670–1674. doi:10.1128/JCM.40.5.1670-1674.2002
   PubMed Web of Science ®Google Scholar
• Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis. 2003;7:6–21.
   PubMed Web of Science ®Google Scholar
• Lemaitre N, Sougakoff W, Truffot-Pernot C, Jarlier V. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemother. 1999;43:1761–1763. doi:10.1128/AAC.43.7.1761
   PubMed Web of Science ®Google Scholar
• Dormandy J, Somoskovi A, Kreiswirth BN, Driscoll JR, Ashkin D, Salfinger M. Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains. Chest. 2007;131:497–501. doi:10.1378/chest.06-1899
   PubMed Web of Science ®Google Scholar
• Scarparo C, Ricordi P, Ruggiero G, Piccoli P. Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method. J Clin Microbiol. 2004;42:1109–1114. doi:10.1128/JCM.42.3.1109-1114.2004
   PubMed Web of Science ®Google Scholar
• Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol. 2010;48:300–301. doi:10.1128/JCM.01775-09
   PubMed Web of Science ®Google Scholar
• Werngren J, Sturegard E, Jureen P, Angebyc K, Hoffner S, Schon T. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing. Antimicrob Agents Chemother. 2012;56:1253–1257. doi:10.1128/AAC.05894-11
   PubMed Web of Science ®Google Scholar
• Simons SO, van Ingen J, van der Laan T, et al. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol. 2012;50:428–434. doi:10.1128/JCM.05435-11
   PubMed Web of Science ®Google Scholar
• Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol. 2010;10:223. doi:10.1186/1471-2180-10-223
   PubMed Web of Science ®Google Scholar
• Chiu YC, Huang SF, Yu KW, Lee YC, Feng JY, Su WJ. Characteristics of pncA mutations in multidrug-resistant tuberculosis in Taiwan. BMC Infect Dis. 2011;11:240. doi:10.1186/1471-2334-11-240
   PubMed Web of Science ®Google Scholar
• Mphahlele M, Syre H, Valvatne H, et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol. 2008;46:3459–3464. doi:10.1128/JCM.00973-08
   PubMed Web of Science ®Google Scholar
• Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE 3rd. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science. 2011;333(6049):1630–1632. doi:10.1126/science.1208813
   PubMed Web of Science ®Google Scholar
• Senqstake S, Berqval IL, Schuitema AR, et al. Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug-resistant TB in Georgia. BMC Infect Dis. 2017;17(1):491. doi:10.1186/s12879-017-2594-3
   Web of Science ®Google Scholar
• World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. World Health Organization; 2018.
   Google Scholar